HuGE Literature Finder
Records
1
-
10
Mechanistic Studies and a Retrospective Cohort Study: The Interaction between PPAR Agonists and Immunomodulatory Agents in Multiple Myeloma. Cancers 2022 11 14 (21): . Wu Jian, Chu Emily, Paul Barry, Kang Yub |
Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways. Frontiers in genetics 2022 2 13 831779. Karagoz Kubra, Stokes Matthew, Ortiz-Estévez María, Towfic Fadi, Flynt Erin, Gooding Sarah, Pierceall William, Thakurta Anj |
Cereblon enhancer methylation and IMiD resistance in multiple myeloma. Blood 2021 6 138 (18): 1721-1726. Haertle Larissa, Barrio Santiago, Munawar Umair, Han Seungbin, Zhou Xiang, Vogt Cornelia, Fernández Rafael Alonso, Bittrich Max, Ruiz-Heredia Yanira, Da Viá Matteo, Zovko Josip, Garitano-Trojaola Andoni, Bolli Niccolò, Ruckdeschel Anna, Stühmer Thorsten, Chatterjee Manik, Kull Miriam, Krönke Jan, Agirre Xabier, Martin-Subero Jose I, Raab Peter, Einsele Hermann, Rasche Leo, Martinez-Lopez Joaquin, Haaf Thomas, Kortüm K Mart |
Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium. Leukemia & lymphoma 2019 Nov 1-8. Iskierka-Ja?d?ewska El?bieta, Canzian Federico, St?pie? Anna, Martino Alessandro, Campa Daniele, Stein Angelica, Krawczyk-Kuli? Ma?gorzata, Rybicka-Ramos Malwina, Kyrcz-Krzemie? S?awomira, Butrym Aleksandra, Mazur Grzegorz, Jurczyszyn Artur, Zawirska Daria, Grz??ko Norbert, Tomczak Waldemar, Subocz Edyta, W?tek Marzena, Pasiarski Marcin, Rymko Marcin, Ca?becka Ma?gorzata, Druzd-Sitek Agnieszka, Walewski Jan, Kruszewski Marcin, Ra?ny Ma?gorzata, Zaucha Jan Maciej, Dudzi?ski Marek, Gaj Pawe?, Robak Tadeusz, Warzocha Krzysztof, Jamroziak Krzyszt |
Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide. Scientific reports 2019 Oct 9 (1): 14884. Huang Phoebe A, Beedie Shaunna L, Chau Cindy H, Venzon David J, Gere Sheryl, Kazandjian Dickran, Korde Neha, Mailankody Sham, Landgren Ola, Figg William |
Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients. British journal of haematology 2019 May . Mlak Rados?aw, Szudy-Szczyrek Aneta, Mazurek Marcin, Szczyrek Micha?, Homa-Mlak Iwona, Mielnik Micha?, Chocholska Sylwia, Jankowska-??cka Olga, Ma?ecka-Massalska Teresa, Hus Mar |
Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients. Leukemia 2019 Apr . Mithraprabhu Sridurga, Morley Rachel, Khong Tiffany, Kalff Anna, Bergin Krystal, Hocking Jay, Savvidou Ioanna, Bowen Kathryn M, Ramachandran Malarmathy, Choi Kawa, Wong Boris Ka Leong, Reynolds John, Spencer Andr |
Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients. Oncotarget 2018 May 9 (35): 24054-24068. Szudy-Szczyrek Aneta, Mlak Rados?aw, Szczyrek Micha?, Chocholska Sylwia, Sompor Jacek, Nogalski Adam, Ma?ecka-Massalska Teresa, Hus Mar |
Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma. Archivum immunologiae et therapiae experimentalis 2017 Jan . Butrym Aleksandra, ?acina Piotr, Rybka Justyna, Chaszczewska-Markowska Monika, Mazur Grzegorz, Bogunia-Kubik Katarzy |
Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment. Leukemia research 2015 Oct . Butrym Aleksandra, Rybka Justyna, ?acina Piotr, G?bura Katarzyna, Frontkiewicz Diana, Bogunia-Kubik Katarzyna, Mazur Grzego |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 22, 2023
- Content source: